Product Data Sheet

Dapsone-d₈

Cat. No.: HY-B0688S CAS No.: 557794-38-4 Molecular Formula: $\mathsf{C}_{12}\mathsf{H}_4\mathsf{D}_8\mathsf{N}_2\mathsf{O}_2\mathsf{S}$

Molecular Weight: 256.35

Target: Bacterial; Reactive Oxygen Species; Antibiotic; Parasite

Pathway: Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κΒ

-20°C 3 years Storage: Powder

In solvent

4°C 2 years -80°C 6 months -20°C 1 month

$$\begin{array}{c|c}
D & NH_2 \\
D & O & D \\
D & D
\end{array}$$

SOLVENT & SOLUBILITY

In Vitro

DMSO: 250 mg/mL (975.23 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.9009 mL	19.5046 mL	39.0092 mL
	5 mM	0.7802 mL	3.9009 mL	7.8018 mL
	10 mM	0.3901 mL	1.9505 mL	3.9009 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description Dapsone-d₈ is a deuterium labeled Dapsone. Dapsone is an orally active and blood-brain penetrant sulfonamide antibiotic with antibacterial, antigenic and anti-inflammatory activities[1]. Dapsone exerts effective antileprosy activity and inhibits folate synthesis in cell extracts of M. leprae. Dapsone can be used as an anticonvulsant and also in the research of skin and glioblastoma diseases[2][3][4][5].

> Dapsone (0.06 mM; 30 min) suppresses intra- and extracellular production of superoxide (O₂-) and elastase release triggered by N-Formyl-Met-Leu-Phe (HY-P0224) (1 µM) and physiological agonist C5a (100 nM), but not by Phorbol 12-myristate 13acetate (HY-18739) (100 nM)^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Dapsone (5 mg/kg; i.p.; single dose) shows neuroprotective effects and substantially improves memory acquisition in Scopolamine (HY-N0296)-induced memory impairment in mice^[6].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vitro

In Vivo

Animal Model:	Scopolamine-induced memory impairment model in mice ^[6]	
Dosage:	0.1, 0.3, 1, 5, and 10 mg/kg; 1 mg/kg for Scopolamine	
Administration:	Intraperitoneal injection; single dose	
Result:	Improved memory acquisition.	

REFERENCES

- [1]. Wozel G, et al. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014 Mar;306(2):103-24.
- [2]. Noroozi N, et al. Protective Effects of Dapsone on Scopolamine-Induced Memory Impairment in Mice: Involvement of Nitric Oxide Pathway. Dement Geriatr Cogn Dis Extra. 2022 Mar 24;12(1):43-50.
- [3]. Y I Zhu, et al. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol
- [4]. Dapsone. Drug.com
- [5]. D Voeller, et al. Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone). J Infect Dis. 1994 Feb;169(2):456-9.
- [6]. Esther Moreno, et al. Evaluation of Skin Permeation and Retention of Topical Dapsone in Murine Cutaneous Leishmaniasis Lesions. Pharmaceutics. 2019 Nov 13;11(11):607.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com\\$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA